CFT7455 is provided in capsule form and administered orally to people with Relapsed/Refractory (r/r) Non-Hodgkin’s Lymphoma (NHL) or Multiple Myeloma (MM). CFT7455 is administered as a single agent (MM and NHL) or in combination with dexamethasone (MM only).
The study medication is an investigational therapy that has been shown in preclinical studies to help the body destroy specific proteins called IKZF1 and IKZF3. These proteins help grow the type of cancer you have. In preclinical lab studies, the study medication has been shown to kill cancer cells by using the body’s own protein-recycling equipment, which is present in the body’s cells, to break down the protein targets IKZF1 and IKZF3. This clinical study is the first time CFT7455 is being tested in humans.
Yes. There is no placebo involved in this study. All participants will receive the study medication. Doses may vary.
Investigational means the study medication is not approved by regulatory authorities like the US Food and Drug Administration (FDA), and it can only be used in clinical research studies like CFT7455-1101. Please talk to your doctor about whether participation in this study may be right for you.